These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9821398)

  • 1. Changes in monitoring of adverse drug reactions in Poland.
    Czarnecki A; Maciejczyk A
    Acta Pol Pharm; 1998; 55(4):319-21. PubMed ID: 9821398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of drugs and adverse drug reactions.
    Maciejczyk A; Czarnecki A
    Acta Pol Pharm; 1997; 54(5):393-5. PubMed ID: 9584696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
    Mariani L; Minora T; Ventresca GP
    Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J; Mejyr S; Bergman U
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.
    Scott HD; Thacher-Renshaw A; Rosenbaum SE; Waters WJ; Green M; Andrews LG; Faich GA
    JAMA; 1990 Apr; 263(13):1785-8. PubMed ID: 2313850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug surveillance: concepts, objectives, and methods].
    Susano RC; Laborinho Fialho L; de Quirós JF
    Acta Med Port; 1992 Dec; 5(11):595-602. PubMed ID: 1293954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adverse reactions from angiotensin-converting enzyme inhibitor drugs reported by the yellow card].
    Morales-Olivas FJ; Ferrer JM; Palop V; Rubio E
    Med Clin (Barc); 1994 Sep; 103(9):321-5. PubMed ID: 7967889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The state of adverse event reporting and signal generation of dietary supplements in Korea.
    Park KS; Kwon O
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reaction assessment in Thailand.
    Sriwatanakul K; Pothisiri P
    Med Toxicol; 1986; 1 Suppl 1():105-9. PubMed ID: 3821423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing surveillance.
    Vlahović-Palčevski V; Mentzer D
    Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing surveillance of adverse drug reactions: patient self-monitoring.
    Fisher S; Bryant SG
    J Am Board Fam Pract; 1992; 5(1):17-25. PubMed ID: 1561919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.